Pfizer Pharmaceutical Company He stopped developing daily birth control pills against obesity, which delayed efforts to find new ways to treat obesity that does not mean periodic injections. The company informed that it would stop studying the medicine Experimental, Danuglipron, after a participant in one of his clinical experiences He will test liver failure The result of the medicine that ended as soon as the person stops treatment.
Version A daily shot of grains It was in the initial testing stageThe researchers tried to determine the best dose for patients, according to a spokeswoman. The company aims to pass the drug to the final stage of the tests, which is usually the last and the most expensive, before the current company Your possible new treatment To the organizational authorities for approval.
A person responsible for the company said in a statement that Fayzar is still planning to develop others Possible treatments against obesity In the previous test stages. Obesity treats has become one of the most promising and profitable sectors for the development of medicines for pharmaceutical companies. Zepbound, de Elie LilyFor example, approximately $ 5,000 million (4.6 billion euros) entered sales in 2024, the first full year in the market.
But the main treatmentsLike Zepbound and Wegovy from Novo Nordisk, they are by injection. Manufacturers are eager to develop the easiest pill version for patients who do not want to deal with daily needles and injection.
Expensive treatments
The researchers hope at night to obtain data from a couple’s studies Oral treatments are possible That developed. Although these drugs have become sales successes, many patients have had difficulty obtaining them, either because of the recent scarc Insurance is unequal coverage.
Laila and New Han announced Price discounts recentlyBut treatments can continue to cost hundreds of euros a month, which puts them away from some people without coverage.
Vizar In late 2023, it was reported that he would leave a copy of Danuglipron twice a day when he advanced to the middle testing stage after more than half of the patients stopped in a clinical trial. A spokeswoman for the company said the decision This means that Pfizer will also stop the Danuglipron experience with other medications to treat obesity.
